Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of “Hold” by Analysts

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have received a consensus recommendation of “Hold” from the nine ratings firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating and four have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $6.75.

A number of research firms have weighed in on ZNTL. Rodman & Renshaw assumed coverage on Zentalis Pharmaceuticals in a report on Thursday, July 23rd. They issued a “buy” rating and a $11.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research report on Monday, July 6th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research report on Friday, May 22nd. Wall Street Zen downgraded shares of Zentalis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Finally, Mizuho started coverage on shares of Zentalis Pharmaceuticals in a report on Friday, July 17th. They set an “outperform” rating and a $8.00 price target for the company.

Insiders Place Their Bets

In other news, major shareholder Group Walters acquired 4,335,000 shares of the firm’s stock in a transaction on Friday, August 14th. The stock was bought at an average cost of $3.50 per share, with a total value of $15,172,500.00. Following the transaction, the insider directly owned 17,844,973 shares in the company, valued at approximately $62,457,405.50. This represents a 32.09% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 3.80% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZNTL. Sivia Capital Partners LLC acquired a new stake in Zentalis Pharmaceuticals during the 4th quarter valued at approximately $27,000. CTC Alternative Strategies Ltd. purchased a new stake in Zentalis Pharmaceuticals during the 1st quarter worth approximately $29,000. Qube Research & Technologies Ltd acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter valued at approximately $37,000. Voleon Capital Management LP acquired a new position in shares of Zentalis Pharmaceuticals in the 3rd quarter valued at approximately $41,000. Finally, State of Wyoming purchased a new position in shares of Zentalis Pharmaceuticals during the 1st quarter valued at approximately $67,000.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $3.84 on Friday. Zentalis Pharmaceuticals has a 1-year low of $1.21 and a 1-year high of $6.95. The business has a 50-day moving average of $4.35 and a 200-day moving average of $3.67. The company has a market capitalization of $275.21 million, a price-to-earnings ratio of -1.97 and a beta of 1.92.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.10). Research analysts expect that Zentalis Pharmaceuticals will post -2.14 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.